Cart
sales@molnova.com
Home -
Products -
Immunology/Inflammation -
PD-1/PD-L1 -
BMS202 hydrochloride (1675203-84-5(free base))
BMS202 hydrochloride (1675203-84-5(free base))
CAS No. 2089334-95-0
BMS202 hydrochloride (1675203-84-5(free base))( —— )
Catalog No. M35287 CAS No. 2089334-95-0
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 97 | In Stock |
|
| 2MG | 54 | In Stock |
|
| 5MG | 97 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 307 | In Stock |
|
| 50MG | 537 | In Stock |
|
| 100MG | 768 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS202 hydrochloride (1675203-84-5(free base))
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM).
-
DescriptionBMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. Binding of BMS202 promotes PD-L1 dimerisation and blocks the PD-L1/ PD1 interaction.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2089334-95-0
-
Formula Weight455.97
-
Molecular FormulaC25H30ClN3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Avelumab
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
-
BMS-200
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM in a homogenous time-resolved fluorescence binding assay.
-
Tislelizumab
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
